Another study showed that GBM cells adapted to temozolomide (TMZ) treatment by increasing the ARL13B–IMPDH2 interaction [13], suggesting that perturbation of this interaction may alter GBM sensitivity to TMZ. Here, IMPDH2 is linked to glioblastoma.